Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 3Colorectal Neoplasms 3Sarcoma 2Rectal Neoplasms 2Neoplasm Metastasis 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Ovarian Neoplasms 1Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × conatumumab × Clear all
NCT00630786 2014-02-06

Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study

Amgen

Phase 1/2 Completed
53 enrolled 13 charts
Gastrointestinal

Colonic Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡